PRIME MEDICINE INC (PRME) Stock Price, Forecast & Analysis
NASDAQ:PRME • US74168J1016
PRME Key Statistics, Chart & Performance
The current stock price of PRME is 4.66 USD. In the past month the price increased by 22.31%. In the past year, price increased by 94.17%.
PRME Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PRME. When comparing the yearly performance of all stocks, PRME is one of the better performing stocks in the market, outperforming 92.65% of all stocks.
PRME Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRME. While PRME has a great health rating, there are worries on its profitability.
PRME Financial Highlights
Over the last trailing twelve months PRME reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 30.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.26% | ||
| ROE | -121.95% | ||
| Debt/Equity | 0 |
PRME Forecast & Estimates
17 analysts have analysed PRME and the average price target is 6.59 USD. This implies a price increase of 41.49% is expected in the next year compared to the current price of 4.66.
For the next year, analysts expect an EPS growth of 18.73% and a revenue growth 515.82% for PRME
PRME Ownership
PRME Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.13 | 410.174B | ||
| AMGN | AMGEN INC | 17.12 | 209.016B | ||
| GILD | GILEAD SCIENCES INC | 16.82 | 184.799B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.84 | 126.056B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.02 | 82.638B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.53 | 43.982B | ||
| INSM | INSMED INC | N/A | 31.848B | ||
| NTRA | NATERA INC | N/A | 28.947B | ||
| BIIB | BIOGEN INC | 12.36 | 28.152B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.44 | 21.698B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRME
Company Profile
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 214 full-time employees. The company went IPO on 2022-10-20. The company deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. The company is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Company Info
PRIME MEDICINE INC
60 First St.
Cambridge MASSACHUSETTS US
Employees: 214
Phone: 13026587581
PRIME MEDICINE INC / PRME FAQ
What does PRME do?
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 214 full-time employees. The company went IPO on 2022-10-20. The company deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. The company is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
What is the stock price of PRIME MEDICINE INC today?
The current stock price of PRME is 4.66 USD. The price increased by 0.87% in the last trading session.
Does PRME stock pay dividends?
PRME does not pay a dividend.
How is the ChartMill rating for PRIME MEDICINE INC?
PRME has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is PRIME MEDICINE INC (PRME) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRME.
What is the market capitalization of PRME stock?
PRIME MEDICINE INC (PRME) has a market capitalization of 841.18M USD. This makes PRME a Small Cap stock.
Who owns PRIME MEDICINE INC?
You can find the ownership structure of PRIME MEDICINE INC (PRME) on the Ownership tab.